Rivaroxaban 10mg/day plus a P2Y12 inhibitor for stroke prevention due to NVAF in patients with renal impairment undergoing PCI with stent placement.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||20/11/2017|
|Rapid review completed||21/11/2017|
|Rapid Review outcome||Full pharmacoeconomic assessment recommended|
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.